SEARCH

SEARCH BY CITATION

References

  • 1
    Fisher B, Redmond C, Dimitrov NV et al. A randomized clinical trial evaluating sequential methotrexate and flourouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473478.
  • 2
    Fisher B, Constantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479484.
  • 3
    Mansour EG, Gray R, Shatila AH et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An Intergroup study. N Engl J Med 1989; 320: 485490.
  • 4
    The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320: 491496.
  • 5
    Spratt JS, Greenberg RA. Validity of the clinical alert on breast cancer. Am J Surg 1990; 159: 195198.
  • 6
    Lee KC. Adjuvant therapy for node-negative breast cancer (Letter). N Engl J Med 1989; 321: 470.
  • 7
    Tannock IF. Adjuvant therapy for node-negative breast cancer (Letter). N Engl J Med 1989; 321: 471472.
  • 8
    McGuire WL. Adjuvant therapy for node-negative breast cancer (Editorial). N Engl J Med 1989; 320: 525527.
  • 9
    McGuire WL, Abeloff MD, Fisher B, Glick JH, Henderson IC, Osborne CK. Adjuvant therapy in node-negative breast cancer: A Panel Discussion. Breast Cancer Res Treat 1989; 13: 97115.
  • 10
    Rosner D, Lane WW. One-third of node-negative breast cancer patients are highly curable by surgery alone, without need for adjuvant systemic therapy (Abstr). Proc Am Soc Clin Oncol 1990; 9: 18.
  • 11
    Rosner D, Lane WW. Identifying additional subsets of low-risk negative-node breast cancer patients, highly curable by surgery alone, who can be spared adjuvant systemic therapy (Abstr). Proc Am Soc Clin Oncol 1991; 10: 49.
  • 12
    Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion; A curable entity using surgery alone without need for adjuvant therapy. Cancer 1991; 67: 14981503.
  • 13
    Rosner D, Lane WW. Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy. Cancer 1990; 66: 199205.
  • 14
    Meyer JS, Province M. Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 1988; 12: 191204.
  • 15
    Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627633.
  • 16
    Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognosis factors in 1331 frozen breast cancer specimens. Cancer 1988; 61: 420427.
  • 17
    Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis: DNA flow cytometry of solid tumors. Cancer 1990; 65: 11941205.
  • 18
    Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erb B-2 Protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103112.
  • 19
    Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 11201128.
  • 20
    Spyratos F, Brouillet JP, Defrenne A et al. Cathepsin D: An independent prognostic factor for metastatic breast cancer. Lancet 1989; 2: 11151119.
  • 21
    McGuire WL, Clark GM. Prognostic factors for recurrence and survival in axillary node-negative breast cancer. J Steroid Biochem 1989; 34: 145148.
  • 22
    LeDoussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 19141921.
  • 23
    Durkin K, Haagensen CD. An improved technique for the study of lymph nodes in surgical specimens. Ann Surg 1980; 191: 419429.
  • 24
    Bloom HJG, Richardson WW. Histological grading and prognosis in breast carcinoma. Br J Cancer 1957; 11: 359377.
  • 25
    Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: A study of 1010 patients, uniformly treated at the Institute Gustave Roussy. J Clin Oncol 1987; 5: 13781386.
  • 26
    Nie NH, Hull CH, Jenkins JG, Steinbrenner K, Bent DH. SPSS: Statistical Package for the Social Sciences, ed 2. New York: McGraw Hill, 1975; 277, 289290.
  • 27
    Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley & Sons, 1980; 1619.
  • 28
    Cox DR. Regression models and life-tables (with discussion). J Roy Stat Soc [B] 1972; 34: 187.
  • 29
    International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990; 335: 15651568.
  • 30
    Fisher ER, Sass R, Fisher B, Collaborating NSABP Investigators. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancer ( Protocol NO. 4): Discriminants for tenth year treatment failure. Cancer 1984; 53: 712723.
  • 31
    Fisher B, Fisher ER, Redmond C, Participating NSABP Investigators. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalinine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 1986; 4: 929941.
  • 32
    Fisher ER. Prognostic and therapeutic significance of pathologic features of breast cancer. NCI Monograph 1986; 2934.
  • 33
    Rosen PP, Kinne DW, Lesser M, Hellman S. Are prognostic factors for local control of breast cancer treated by primary radiotherapy significant for patients treated by mastectomy? Cancer 1986; 57: 14151420.
  • 34
    Russo J, Frederick J, Ownby HE et al. Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 1987; 88: 123131.
  • 35
    Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation in breast carcinoma: Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis and mitotic count. Cancer 1990; 65: 11801184.
  • 36
    Meyer JS. An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989; 64: 19141921.
  • 37
    Kallioniemi OP, Blanco G, Alavaikko M et al. Tumor DNA ploidy as an independent prognostic factor in breast cancer. Br J Cancer 1987; 56: 637642.
  • 38
    Owaineti AAR, Robins RA, Hinton C et al. Tumor aneuploidy, prognostic parameters and survival in primary breast cancer. Br J Cancer 1987; 55: 449454.
  • 39
    Thorud E, Fossa SD, Vaage S et al. Primary breast cancer: Flow cytometric DNA pattern in relation to clinical and histopathologic characteristics. Cancer 1986; 57: 808811.
  • 40
    Moran RE, Black MM, Alpert L, Straus MJ. Correlation of cell kinetics, hormone receptors, histopathology, and nodal status in human breast cancer. Cancer 1984; 54: 15861590.
  • 41
    McDivitt RW, Stone KR, Craig RB, Palmer JO, Meyer JS, Bauer WC. A proposed classification of breast cancer based on kinetic information. Cancer 1986; 57: 269276.
  • 42
    Gilchrist KW, Kalish L, Gould VE et al. Interobserver reproducibility of histopathologic features in stage II breast cancer. Breast Cancer Res Treat 1985; 5: 310.
  • 43
    Davis BW, Gelberg RD, Goldhirsch A et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 1986; 58: 26622670.
  • 44
    Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N On behalf of the Danish Breast Cancer Cooperative Group. Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 1987; 47: 61266133.
  • 45
    Chevalier B, Heintzman F, Mosseri V et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis. Cancer 1988; 62: 25172524.
  • 46
    Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: A retrospective analysis of 176 cases. Cancer 1990; 65: 17941800.
  • 47
    McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. C-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990; 65: 8892.
  • 48
    Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR. Increased erb B-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990; 50: 67016717.
  • 49
    McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987; 10: 59.
  • 50
    Fallenius AG, Auer GU, Carstensen JM. Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 1988; 62: 331341.
  • 51
    Ewers S-B, Langstrom E, Baldetorp B, Killander D. Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. Cytometry 1984; 5: 408419.
  • 52
    Uyterlinde AM, Schipper NW, Baak JPA. Comparison of extent of disease and morphometric and DNA flow cytometric prognostic factors in invasive ductal breast cancer. J Clin Pathol 1987; 40: 14321436.
  • 53
    Winchester DJ, Duda RB, August CZ et al. The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg 1990; 125: 886889.
  • 54
    National Institute of Health. Consensus development conference statement: Treatment of early stage breast cancer. June 18–21, 1990. Bethesda, MD: National Institute of Health.
  • 55
    McGuire WH, Tandon AK, Allzed C, Chomness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 10061015.
  • 56
    Curtis RE, Boice JD, Molomey WC, Ries LG, Flannery JT. Leukemia following chemotherapy for breast cancer. Cancer Res 1990; 50: 27412746.
  • 57
    Geller B, Boone LB, Karp JE et al. Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma: A new complication of cyclophosphamide, methotrexate and 5-flourouracil therapy. Cancer 1989; 64: 629634.
  • 58
    Love RS. Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects. J Clin Oncol 1989; 7: 803815.
  • 59
    Sigurdsson H, Baldetorp B, Borg A et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 10451053.
  • 60
    Skehan P. Cell growth, tissue neogenesis, and neoplastic transformation. In: SkehanP, FriedmanSJ, eds. Growth, Cancer, and the Cell Cycle. Clifton, NJ: Humana Press, 1984; 323345.